Assembly Biosciences Inc. (ASMB) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±10.6% realized swing band)
FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 35.9 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ASMB currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($26.14) and Max Pain ($21.90) forces dealer call-delta covering toward $41.70.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Assembly Biosciences Inc. (ASMB) advanced +1.41% to $20.86, trading at 8% of its 52-week range ($19.3 – $39.71). Stretched risk/reward at current multiples (-7% return on capital) under elevated 10-year interest-rate pressure.
– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection –– Initial data from the Phase 2 study is expected in the fourth quarter of 2027 –
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced dosing of the first two participants in a Phase 2 clinical
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +153.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ASMB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ASMB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Assembly Biosciences Inc. (ASMB) ranks #917 by composite RQD confidence (31/100, grade E) and #472 by equity capitalization ($424.7M). Within this direct 5-issuer industry benchmark cohort, ASMB leads on earnings valuation at N/A trailing P/E, while ASMB leads on capital efficiency and profitability with -6.5% ROIC and — gross margin. ALT currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with ASMB at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ASMB
ACTIVE
Assembly Biosciences Inc. | E | 31/100 | — | — | -6.5% | +1.41% | $424.7M | Benchmark Subject |
| ALT Altimmune Inc. | D- | 38/100 | — | — | -34.7% | +1.91% | $416.3M | /alt-vs-asmb → |
| AVTX Avalo Therapeutics Inc. | E | 34/100 | — | — | -35.0% | +4.49% | $399.0M | /avtx-vs-asmb → |
| RZLT Rezolute Inc. (NV) | E | 33/100 | — | — | -35.0% | -2.37% | $398.5M | /rzlt-vs-asmb → |
| PRTA Prothena Corporation plc | E | 24/100 | — | — | -35.0% | -2.42% | $455.9M | /prta-vs-asmb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Assembly Biosciences Inc. (ASMB) reported GAAP revenue of $72.3M (+153.5% vs. FY2024 revenue of $28.5M ) , GAAP net income of -$6.1M, operating cash flow of -$41.1M, and free cash flow of -$41.2M (+19.5% YoY). On the balance sheet, ASMB closed FY2025 with $257.6M in total assets against $0 in total debt (Altman Z-Score: 1.57, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $72.3M | -$6.1M | -$41.1M | -$41.2M | $257.6M | — |
| FY2024 (FY) | 2024-12-31 | $28.5M | -$40.2M | -$51.1M | -$51.1M | $119.2M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$61.2M | $22.7M | $22.7M | — | — |
As of 2026-11-01, Assembly Biosciences Inc. (NASDAQ: ASMB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $20.86 (+1.41% 1D, market cap $424.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ASMB ranks #917 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ASMB carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -6.5%. By comparison, ALT (Altimmune Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -34.7%, cap $416.3M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $399.0M). Among the 5-stock peer group, ASMB leads on earnings multiple (N/A) while ASMB leads on capital efficiency (-6.5% ROIC).
Per ASMB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001426800), Assembly Biosciences Inc. generated $72.3M in revenue (+153.5% YoY), -$6.1M in net income, and -$41.2M in free cash flow against $257.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ASMB last traded at $20.86 (+1.41% on volume of 198,764 shares), positioning the stock -20.20% below its 50-day simple moving average ($26.14) and -23.31% below its 200-day simple moving average ($27.20). Across its 52-week range of $19.30 to $39.71, ASMB sits at the 7.6% percentile with a 14-day RSI of 35.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($18.65 to $23.07).
Why ASMB Stock advanced +1.41% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-7% return on capital) under elevated 10-year interest-rate pressure.